Past Colloquia – 2012 – UCSD Medical Scientist Education Program

Thursday August 2

Clark Chen, MD, Ph.D. UCSD Neurosurgery

Jonathan Lynn, MD, Ph.D. UCSD Pathology

Seth Field, MD, Ph.D. Internist UCSD

the Academic Track for MD/Ph.Ds: A panel discussion with early-career UCSD faculty

Each summer, the Physician Scientist Colloquium welcomes faculty panelists to discuss a topic of interest to the Physician Scientist community. At this event, we invited UCSD MD/PhD professors from various departments to discuss their experiences as scholars. The academic track is one of many available to MSTP graduates, but it is often considered the “default” path. We hope this event will be informative and provide current students with an in-depth and honest look at this career path. We look forward to a thought-provoking discussion from Dr. Chen (neurosurgery), Dr. Lin (pathology) and Seth Field (internal medicine), moderated by MSTP student Sagar Bapat

Thursday May 24

Seung K. Kim, MD, Ph.D. Stanford MSTP Director HHMI, Professor of Developmental Biology

Dr. Kim’s Experiences as a Physician Scientist and Director of Stanford’s STD Program

dr. Seung Kim is Howard Hughes Medical Researcher and Professor of Developmental Biology at Stanford University. His research laboratory has developed new approaches to create, grow and regenerate pancreatic islet cells and also studies the development and growth of the pancreas. He is also a a graduate of Stanford’s Medical Scientist Training Program (1992), AND sixteen years later, in 2008, he became its director! Which of the current MSTPs will take over Paul’s job in sixteen years??

Thursday March 22

Harry E. Gruber, MD Tocagen Inc. President/CEO/President

Research in progress: Joshua Theisen MSTP Student, Kadonaga Lab

Career Prospects: Industry Experiences

dr. Gruber holds a BA and MD from the University of Pennsylvania. After 9 years at UCSD as a geneticist, rheumatologist and researcher, Dr. Gruber began a career in the industry by founding Gensia, Inc.. in 1986, one of the first gene therapy companies that went public in 1990 and had a market capitalization of $1.7 billion. dr. Gruber have founded web solutions companies Intervened (sold 2.8 billion… yes, with a “b”) and Kintera (helping nonprofits raise funds and awareness) in the 90s, and now leads tocagen, a company dedicated to the development and commercialization of breakthrough cancer treatments using advanced gene transfer technologies

Thursday February 2

Dan Littman MD Ph.D.
Professor of Molecular Immunology and Professor of Pathology and Microbiology, Howard Hughes Medical Institute Researcher, New York University Langone Medical Center

Current Research: Justin Voog, Ph.D. MSTP student

Career opportunities : Dan Littman has worked on HIV for nearly 30 years, cloned CD4 while working with Richard Axel at Columbia University, is a giant in the field of T cell development and biology, and was an HHMI researcher for over 20 years at UC San Francisco and New York University.

Wednesday January 18

Paul Mischel, MD Professor of Pathology and Laboratory Medicine, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA

Currently researching : Michael Lam, Ph.D. MSTP studentglass laboratory

Career opportunities : Paul Michaeldoctor, is the Lya and Harrison Latta Professor of Pathology and Laboratory Medicine in the Department of Molecular and Medical Pharmacology and the David Geffen School of Medicine at UCLA. dr. Michael graduated from Alpha Omega Alpha with an MD from Cornell University Medical College and trained in Anatomical Pathology and Neuropathology at UCLA. dr.Michael received his postdoctoral research training in the laboratory of Dr. Louis F. Reichardt at UCSF’s Howard Hughes Medical Institute and joined the UCLA faculty in 1998. dr.Michael has received numerous awards, including the Farber Prize in 2007, the most prestigious award for brain tumor research given jointly by the Society for Neuro-oncology and the American Association of Neurosurgery.
Come hear Paul Michael reflect on his career choices and his vision of the life of a doctor-researcher and of biomedical sciences during our next colloquium of doctor-researchers.